CTLA4 and neoplasm: Figure 5B illustrated that tumor mutation burden (TMB) has a negative correlation with FLT3 expression. It was verified that IPS has the potential to predict the treatment response to ICIs (Charoentong et al., 2017). The IPS data was acquired from the TCIA webpage to explore the relevance of FLT3 expression to IPS. The FLT3-highly-expressed subgroup had a statistically higher IPS- CTLA4 or PD1/PD-L1/PD-L2 score or IPS- CTLA4 and PD1/PD-L1/PD-L2 score (Figures 5C–E).